17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12384753-B2
Application number	US-202217891436-A
Country	US
Kind code	B2
Filing date	Aug 19, 2022
Priority date	Aug 20, 2021
Publication date	Aug 12, 2025
Grant date	Aug 12, 2025

Abstract

The present invention provides compounds of Formula (I),

pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

First claim

What is claimed:

1. A compound represented by one of Formulas (X-2), (X-3), (X-4), (X-5), (X-6), (X-11) and (X-12), or a pharmaceutically acceptable salt thereof:

wherein each R 11 is independently selected from the group consisting of halogen, hydroxy, —NH 2 , —NHMe, —NMe 2 , —CN, —NO 2 , optionally substituted-C 1 -C 6 alkyl, optionally substituted-C 1 -C 6 alkoxyl, optionally substituted-C 3 -C 6 cycloalkyl, optionally substituted-C 3 -C 6 cycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl; n is 0, 1, 2, or 3; each R 12 is independently selected from the group consisting of halogen, hydroxy, —NH 2 , —NHMe, —NMe 2 , —CN, —NO 2 , optionally substituted-C 1 -C 6 alkyl, optionally substituted-C 1 -C 6 alkoxyl, optionally substituted-C 3 -C 6 cycloalkyl, optionally substituted-C 3 -C 6 cycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl; m is 0, 1 or 2; R 13 is selected from the group consisting of hydrogen, halogen, hydroxy, —NH 2 , —NHMe, —NMe 2 , —CN, —NO 2 , optionally substituted-C 1 -C 6 alkyl, optionally substituted-C 1 -C 6 alkoxyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 3 -C 6 cycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl;

 is optionally substituted aryl; and

 is optionally substituted-C 3 -C 12 cycloalkyl, optionally substituted 3- to 12-membered heterocycloalkyl, or optionally substituted-C 3 -C 12 cycloalkenyl.

2. The compound of claim 1 , represented by one of Formulas (XI-3) to (XI-14) and (XI-17) to (XI-22), or a pharmaceutically acceptable salt thereof:

wherein m, R 12 , R 13 ,

are as defined in claim 1 .

3. The compound of claim 2 , represented by Formula (XI-9) or (XI-10), or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , represented by Formula (X-5), or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , selected from the compounds set forth in the table below, or a pharmaceutically acceptable salt thereof:

Compound

#
Structure

281

284

300

303

336

340

346

348

349

350

351

352

353

366

367

368

Assignees

• Enanta Pharm Inc

Inventors

• Wang Guoqiang
• Ma Jun
• Granger Brett
• Long Jiang
• Wang Bin
• Ghorai Sourav
• He Jing
• He Yong
• Xing Xuechao
• Shen Ruichao
• Or Yat Sun

Classifications

• C07D471/04

  Ortho-condensed systems · CPC title

• C07D417/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D417/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D307/81

  Radicals substituted by nitrogen atoms not forming part of a nitro radical · CPC title

• C07D277/36 Primary

  Sulfur atoms · CPC title